Sarcoma

Summary

The Sarcoma research group, led by Òscar Martinez-Tirado, is a multidisciplinary group which primarily aims to identify new metastatic markers and broaden the knowledge regarding their biological role in developing sarcomas, as well as identifying new therapeutic targets and validating new prognostic and predictive markers in sarcomas, through preclinical evaluation of new components for their treatment. This preclinical evaluation includes epigenetic, proapoptotic and cell-cycle-blocking drugs.

147 Publications

Strategic lines

Selected Publications

Santana Viera,L;Dassie,JP;Rosàs Lapeña,M;Garcia Monclús,S;Chicón Bosch,M;Pérez Capó,M;Pozo,LD et al, Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors., Mol. Ther.-Nucl. Acids, 2023;32758-772, doi:10.1016/j.omtn.2023.05.003
Santana Viera,L;Dassie,JP;Rosàs Lapeña,M;Garcia Monclús,S;Chicón Bosch,M;Pérez Capó,M;Pozo,LD et al, Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors., Mol. Ther.-Nucl. Acids, 2023;32758-772, doi:10.1016/j.omtn.2023.05.003
Moratalla Navarro,F;Diez Villanueva,A;Garcia Serrano,A;Closa,A;Cordero,D;Sole,X;Guino,E et al, Identification of a Twelve-microRNA Signature with Prognostic Value in Stage II Microsatellite Stable Colon Cancer, Cancers, 2023;15(13):doi:10.3390/cancers15133301,
Lauritsen,J;Sauvé,N;Tryakin,A;Jiang,DM;Huddart,R;Heng,DYC;Terbuch,A et al, Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database, Br. J. Cancer, 2023;doi:10.1038/s41416-023-02443-3
Sternberg,CN;Petrylak,DP;Bellmunt,J;Nishiyama,H;Necchi,A;Gurney,H;Lee,JL et al, FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression., J. Clin. Oncol., 2023;41(3):629-639, doi:10.1200/JCO.21.02303

Selected Projects

FIS23059. Terapia de tumores de células germinales basada en linfocitos infiltrantes de tumores autólogos (ARES). Instituto de Salud Carlos III (ISCIII). Budget: 1.205.077,03€. 2024-2027. PI: GARCIA DEL MURO SOLANS, FRANCISCO JAVIER.
FIS21126. Tratamiento con TILs en tumores avanzados con alteraciones del complejo SWI/SNF: El estudio TILTS. Instituto de Salud Carlos III (ISCIII). Budget: 1.081.914,72€. 2022-2025. PI: MARTIN LIBERAL, JUAN JESUS.
21ACL082. MK-6482-012. MERCK SHARP & DOHME ESPAÑA S.A. Budget: 413.311,5€. 2021- . PI: García del Muro Solans, F. Xavier.
19ACL046. ENSAYO DE FASE 3, ALEATORIZADO Y CONTROLADO CON PLACEBO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE PEMBROLIZUMAB (MK-3475) Y LENVATINIB (E7080/MK-7902) EN COMPARACIÓN CON PEMBROLIZUMAB EN MONOTERAPIA COMO INTERVENCIÓN DE PRIMERA LÍNEA EN PARTICIPANTES CON MELANOMA AVANZADO (LEAP-003). MERCK SHARP & DOHME ESPAÑA S.A.. Budget: 376.776€. 2019-2024. PI: Martín Liberal, Juan.
20ACL004. ESTUDIO DE FASE 1, ABIERTO, MULTICÉNTRICO Y DE VARIOS GRUPOS DE MK-1308 EN COMBINACIÓN CON PEMBROLIZUMAB EN SUJETOS CON TUMORES SÓLIDOS AVANZADOS. MERCK SHARP & DOHME ESPAÑA S.A. Budget: 289.220€. 2020-2999. PI: Martín Liberal, Juan.